Gene · 1806
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,061 to 1,080 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic diversity of 'Very Important Pharmacogenes' in two South-Asian populations. | PeerJ | 2021 | 34824904 | PubTator, text mining | PubMed |
| Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma. | Ecancermedicalscience | 2021 | 34824615 | PubTator, text mining | PubMed |
| Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer. | BMC Cancer | 2021 | 34819038 | PubTator, text mining | PubMed |
| Universal probe-based intermediate primer-triggered qPCR (UPIP-qPCR) for SNP genotyping. | BMC Genomics | 2021 | 34819030 | PubTator, text mining | PubMed |
| Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature. | World J Surg Oncol | 2021 | 34809643 | PubTator, text mining | PubMed |
| Genetic Polymorphisms in Pharmaceuticals and Chemotherapy. | World J Oncol | 2021 | 34804277 | PubTator, text mining | PubMed |
| Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China. | BMC Genom Data | 2021 | 34798807 | PubTator, text mining | PubMed |
| Modern Approaches to Testing Drug Sensitivity of Patients' Tumors (Review). | Sovrem Tekhnologii Med | 2021 | 34795997 | PubTator, text mining | PubMed |
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). | BMC Cancer | 2021 | 34794396 | PubTator, text mining | PubMed |
| Identification of biomarkers and ceRNA network in glioblastoma through bioinformatic analysis and evaluation of potential prognostic values. | Ann Transl Med | 2021 | 34790767 | PubTator, text mining | PubMed |
| Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. | N Z Med J | 2021 | 34788277 | PubTator, text mining | PubMed |
| Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil. | BMC Cancer | 2021 | 34774016 | PubTator, text mining | PubMed |
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. | Cancers (Basel) | 2021 | 34771635 | PubTator, text mining | PubMed |
| Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey. | Cancers (Basel) | 2021 | 34771628 | PubTator, text mining | PubMed |
| Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma. | Cancers (Basel) | 2021 | 34771601 | PubTator, text mining | PubMed |
| Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. | Int J Mol Sci | 2021 | 34769209 | PubTator, text mining | PubMed |
| Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. | MedComm (2020) | 2021 | 34766149 | PubTator, text mining | PubMed |
| Discordant associations of educational attainment with ASD and ADHD implicate a polygenic form of pleiotropy. | Nat Commun | 2021 | 34764245 | PubTator, text mining | PubMed |
| Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. | World J Gastroenterol | 2021 | 34754151 | PubTator, text mining | PubMed |
| Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials. | Sci Rep | 2021 | 34754015 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1806/papers?page=54